Halozyme Therapeutics Inc
HALO59.745USD
+0.725+1.23%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
7.36BCap. mercado
15.16P/E TTM
Más Datos de Halozyme Therapeutics Inc Compañía
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Información de la empresa
Símbolo de cotizaciónHALO
Nombre de la empresaHalozyme Therapeutics Inc
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoDr. Helen I. Torley
Número de empleados350
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección12390 El Camino Real
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92130
Teléfono18587948889
Sitio Webhttps://www.halozyme.com/
Símbolo de cotizaciónHALO
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoDr. Helen I. Torley
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.90K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Ms. Barbara Duncan
Ms. Barbara Duncan
Independent Director
Independent Director
--
--
Ms. Tram Bui
Ms. Tram Bui
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
733.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
31.90K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
168.19M
63.50%
Sales of proprietary products
36.34M
13.72%
Sales of bulk rHuPH20
27.02M
10.20%
Sales-based milestones
15.00M
5.66%
Sales of device partnered products
14.68M
5.54%
Other
3.63M
1.37%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
168.19M
63.50%
Sales of proprietary products
36.34M
13.72%
Sales of bulk rHuPH20
27.02M
10.20%
Sales-based milestones
15.00M
5.66%
Sales of device partnered products
14.68M
5.54%
Other
3.63M
1.37%
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
10.39%
State Street Global Advisors (US)
4.91%
Snyder Capital Management, L.P.
2.98%
AllianceBernstein L.P.
2.61%
Other
66.94%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.16%
The Vanguard Group, Inc.
10.39%
State Street Global Advisors (US)
4.91%
Snyder Capital Management, L.P.
2.98%
AllianceBernstein L.P.
2.61%
Other
66.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
58.36%
Investment Advisor/Hedge Fund
30.60%
Research Firm
4.57%
Pension Fund
2.37%
Hedge Fund
1.88%
Bank and Trust
1.48%
Sovereign Wealth Fund
1.16%
Individual Investor
1.11%
Insurance Company
0.12%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1032
125.13M
101.55%
-10.49M
2025Q1
1043
127.91M
103.79%
-10.64M
2024Q4
999
127.73M
103.64%
-14.45M
2024Q3
953
129.39M
102.16%
-10.33M
2024Q2
905
126.24M
99.18%
-14.91M
2024Q1
870
127.71M
100.45%
-13.70M
2023Q4
850
128.82M
97.51%
-11.71M
2023Q3
836
127.73M
96.80%
-13.97M
2023Q2
838
128.24M
97.33%
-12.36M
2023Q1
833
129.53M
95.63%
-10.61M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
14.99M
12.16%
-268.69K
-1.76%
Mar 31, 2025
The Vanguard Group, Inc.
12.80M
10.39%
-451.45K
-3.41%
Mar 31, 2025
State Street Global Advisors (US)
6.05M
4.91%
-1.13M
-15.75%
Mar 31, 2025
Snyder Capital Management, L.P.
3.67M
2.98%
-494.15K
-11.85%
Mar 31, 2025
AllianceBernstein L.P.
3.22M
2.61%
+146.68K
+4.78%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.17M
2.57%
+105.17K
+3.43%
Mar 31, 2025
Macquarie Investment Management
2.67M
2.17%
-231.21K
-7.96%
Mar 31, 2025
Invesco Capital Management LLC
2.42M
1.96%
+628.59K
+35.15%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.03M
1.65%
+95.60K
+4.94%
Mar 31, 2025
Congress Asset Management Company, LLP
2.13M
1.73%
+172.97K
+8.83%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Future Fund Long/Short ETF
3.76%
First Trust NYSE Arca Biotechnology Index Fund
2.71%
Invesco Biotechnology & Genome ETF
2.54%
SPDR S&P Biotech ETF
2.35%
Congress SMid Growth ETF
2.21%
Janus Henderson Small Cap Growth Alpha ETF
2.05%
Invesco S&P MidCap 400 GARP ETF
1.92%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.92%
Virtus LifeSci Biotech Products ETF
1.84%
Alpha Architect US Quantitative Value ETF
1.84%
Ver más
Future Fund Long/Short ETF
Proporción3.76%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.71%
Invesco Biotechnology & Genome ETF
Proporción2.54%
SPDR S&P Biotech ETF
Proporción2.35%
Congress SMid Growth ETF
Proporción2.21%
Janus Henderson Small Cap Growth Alpha ETF
Proporción2.05%
Invesco S&P MidCap 400 GARP ETF
Proporción1.92%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción1.92%
Virtus LifeSci Biotech Products ETF
Proporción1.84%
Alpha Architect US Quantitative Value ETF
Proporción1.84%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
